S-4327-119
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsored by Tom Cotton (R-AR)
What it does
This bill would require the FDA to review all drug applications — both new and those submitted since January 1, 2016 — to determine whether the sponsor is affiliated with the Chinese government, the Chinese Communist Party, or the People's Liberation Army. It would prohibit FDA approval of any new drug application from such an entity and would block the import of already-approved drugs tied to those entities, with exceptions for drug shortage situations. Companies could avoid the import ban by demonstrating they have severed ties with the Chinese government or by selling their approved drug applications to a non-affiliated entity within 180 days. The bill authorizes $5 million to fund implementation.
Who benefits
U.S.-based pharmaceutical manufacturers and generic drug makers who compete with Chinese-affiliated companies and would face less competition. Domestic active pharmaceutical ingredient (API) producers who could gain market share. Patients and public health advocates concerned about supply chain security and the integrity of drugs sourced from Chinese entities. National security-focused policymakers seeking to reduce U.S. dependence on Chinese pharmaceutical supply chains. Alternative foreign suppliers (e.g., Indian, European) who may fill gaps left by excluded Chinese products.
Who is hurt
Patients who rely on lower-cost generic drugs, many of which are manufactured in or sourced from China, and who could face higher prices or shortages if supply is disrupted. Hospitals and pharmacies dependent on Chinese-sourced active pharmaceutical ingredients for common medications. U.S. companies that license drug formulations or ingredients from Chinese entities and would need to restructure supply chains. Chinese pharmaceutical companies with U.S. market access. Distributors and importers of Chinese-origin pharmaceuticals. Patients in drug shortage situations, though a waiver provision partially mitigates this risk.
Supporters argue
Supporters argue that China supplies a dominant share of the active pharmaceutical ingredients used in U.S. generic drugs — estimates suggest roughly 80% of API supply chains have some Chinese component — creating a critical national security vulnerability. They contend that allowing Chinese government-affiliated entities to hold FDA-approved drug applications gives the PRC potential leverage over U.S. healthcare during a conflict or diplomatic crisis, and that the bill's compliance pathway and drug shortage waiver make it targeted rather than sweeping.
Opponents argue
Opponents argue that broadly barring drugs from Chinese-affiliated entities could worsen the very drug shortages the bill seeks to prevent, given how deeply integrated Chinese manufacturers are in the global generic drug supply chain. They contend that the bill's definition of "PRC-, CCP-, or PLA-affiliated entity" — which includes any entity receiving indirect support or having a board member with ownership ties — is broad enough to sweep in companies with only nominal government connections, potentially disrupting supply of critical medications for millions of Americans.
Constitutional context
Congress has broad authority to regulate drug imports and pharmaceutical approvals under the Commerce Clause (Art. I, §8, cl. 3) and the Necessary and Proper Clause. Post-Loper Bright (2024), FDA's implementation of the broad "affiliated entity" definition would receive no automatic judicial deference, meaning courts would independently assess whether the agency's determinations stay within the statute's bounds — a meaningful check on how expansively the FDA applies the affiliation criteria.
Checks and balances
The Executive Branch (FDA/HHS) gains significant new authority to deny drug approvals and block imports based on national security determinations; checks include the bill's compliance and waiver processes, the drug shortage exception, the statutory 180-day divestiture window, and post-Loper Bright judicial review of FDA affiliation determinations.
Historical precedent
The BIOSECURE Act (proposed 2024) similarly sought to restrict U.S. federal contracts with specific Chinese biotechnology companies, reflecting a parallel legislative approach to Chinese pharmaceutical supply chain security.